Related Experiment Video
Updated: May 21, 2026

An In Vitro Bladder Model of Catheter-Associated Urinary Tract Infection
Published on: June 24, 2025
Antibiotic prophylaxis in catheter-associated urinary infections
Pasquale Petronella1, Marco Scorzelli, Andrea Fiore
1Second University of the Study of Naples, Department of Gerontology, Naples, Italy. pasquale.petronella@unina2.it
Abstract:
This study aimed to assess the usefulness of antibiotic prophylaxis with Levofloxacin (LVFX) in short and mediumterm catheterisations. This study was developed to evaluate and confirm the effectiveness and need for prophylaxis in preventing catheter-associated UTIs, using LVFX at a dose of 250 mg administered orally to patients who had been subjected to short and medium-term urinary bladder catheterisation following surgery (3-14 days). The study was designed as a phase III study with parallel groups, multicentre, randomised, controlled with a placebo in three groups. The study was double-blind in treatment groups A and B and single-blind in group C. The study involved the recruitment of 120 patients, 40 for each treatment group. We show two types of results, one based on primary effectiveness variables and the other on the secondary effectiveness variables. The group treated with LVFX displayed a greater tendency toward the negativisation of bacteriuria and pyuria tests than that recorded for the placebo group, and was essentially comparable to that recorded for the group of patients treated with Ciprofloxacin. We can thus affirm that LVFX may be useful for preventing short and medium-term CAUTIs.
Related Concept Videos
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Urinary Tract Infection IV: Nursing Management
Urine Studies II: Urine Culture and Sensitivity Test
Acute Pyelonephritis II: Diagnostic Studies and Management
Urinary Tract Infection II: Pathophysiology
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...

